Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark S Freedman

Showing results (11-20 of 277) with videos related to

Pageof 28
Sort By:
Expert Opinion on Pharmacotherapy|October 6, 2006
Disease-modifying drugs for multiple sclerosis: current and future aspectsMark S Freedman
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 5, 2012
Do not treat from CIS onset: evaluate disease course and prognosis first--no (treat!)Mark S Freedman
Neurology. Clinical Practice|February 15, 2018
Multiple sclerosis therapeutic strategies: Use second-line agents as first-line agents when time is of the essenceMark S Freedman
Expert Opinion on Biological Therapy|June 27, 2014
Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosisMark S Freedman
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 11, 2015
Are we in need of NEDA?Mark S Freedman
Journal of the Neurological Sciences|June 15, 2007
Bone marrow transplantation: does it stop MS progression?Mark S Freedman
Clinical Neurology and Neurosurgery|April 6, 2010
Therapy of MSReza Vosoughi, Mark S Freedman
The Lancet. Neurology|January 13, 2012
Neurorepair with mesenchymal stem cells: hope or hype?Mark S Freedman, Antonio Uccelli
Journal of the Neurological Sciences|January 26, 2021
Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosisGauruv Bose, Mark S Freedman
Expert Review of Neurotherapeutics|October 9, 2012
Disease-specific therapy of idiopathic inflammatory demyelinating disordersMohsen Khoshnam, Mark S Freedman
Pageof 28

Showing results (11-20 of 277) with videos related to

Sort By:
Pageof 28
Expert Opinion on Pharmacotherapy|October 6, 2006
Disease-modifying drugs for multiple sclerosis: current and future aspectsMark S Freedman
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 5, 2012
Do not treat from CIS onset: evaluate disease course and prognosis first--no (treat!)Mark S Freedman
Neurology. Clinical Practice|February 15, 2018
Multiple sclerosis therapeutic strategies: Use second-line agents as first-line agents when time is of the essenceMark S Freedman
Expert Opinion on Biological Therapy|June 27, 2014
Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosisMark S Freedman
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 11, 2015
Are we in need of NEDA?Mark S Freedman
Journal of the Neurological Sciences|June 15, 2007
Bone marrow transplantation: does it stop MS progression?Mark S Freedman
Clinical Neurology and Neurosurgery|April 6, 2010
Therapy of MSReza Vosoughi, Mark S Freedman
The Lancet. Neurology|January 13, 2012
Neurorepair with mesenchymal stem cells: hope or hype?Mark S Freedman, Antonio Uccelli
Journal of the Neurological Sciences|January 26, 2021
Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosisGauruv Bose, Mark S Freedman
Expert Review of Neurotherapeutics|October 9, 2012
Disease-specific therapy of idiopathic inflammatory demyelinating disordersMohsen Khoshnam, Mark S Freedman
Pageof 28